Efficacy and Safety of Synchronized Cardiac Support in Cardiogenic Shock Patients
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-85
SponsorXenios AG
About this trial
The study aims to investigate the safety and efficacy of the Synchronized Cardiac Support treatment wit the icor kit and the Xenios console with modified sensor box ECG and Software Version 3.2.4
Eligibility criteria
Qualifiers
Informed consent signed and dated by study patient/legal representative and investigator/authorised physician
Minimum age of 18 years
Patients in cardiogenic shock
Systolic blood pressure < 90 mmHg for at least 30 min
Disqualifiers
In case of female patients: pregnancy or lactation period
Participation in an interventional clinical study during the preceding 30 days
Previous participation in the same study
Age > 85 years
Trial design
Treatments tested in this trial
- Synchronized Cardiac Support with the icor kit
Treatment groups
21 Participants
are divided into 1 treatment groupLocations
2Krankenhaus Buchholz und Winsen gGmbH21244, Buchholz Germany
Elisabeth-Krankenhaus Essen GmbH45138, Essen Germany
Sponsors and collaborators
Xenios AG
Lead sponsor
Source ClinicalTrials.gov